CardioMetabolic Disease Research

Boehringer Ingelheim sets the bar high for innovation in cardiometabolic diseases. We have a strong legacy of ‘firsts’, extending over many decades, which have revolutionized the treatment landscape. Most recently this includes empagliflozin which is the first type 2 diabetes treatment approved to reduce cardiovascular death^* in patients with type 2 diabetes and established cardiovascular disease. But our scientists are also looking to the future and examining their research through a new lens to investigate the next generation of breakthrough medicines for patients.

^* Approved by the US FDA